On April 15, 2026 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported that it will present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held from April 17–22, 2026, in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will include details around the IND-enabling activities for the company’s potent STING Agonist, IMGS-203, for the treatment of GBM. This therapy is designed for intratumoral delivery, enabling localized immune activation with minimal systemic exposure. In orthotopic GBM models, IMGS-203 demonstrated robust anti-tumor activity and significant survival benefit. The data support a clear translational path, with pharmacologic activity confirmed across multiple species and pilot toxicology studies informing dose and delivery parameters for the GLP toxicology study and eventual clinical trial.
"IMGS-203 combines potent STING activation with a localized delivery approach designed to overcome the immunosuppressive tumor microenvironment in GBM," said Dr. Federica Pericle, Chief Scientific Officer of ImmunoGenesis. "These data support the advancement of IMGS-203 toward clinical development."
IMGS-203 Presentation Details:
GBM is a lethal malignancy with a highly immunosuppressive tumor microenvironment (TME) enriched in myeloid-derived suppressor cells, tumor-associated macrophages, and tumor-associated neutrophils. IMGS-203 is a potent STING agonist developed for intratumoral (IT) delivery, a route of administration (ROA) particularly suited for GBM, a tumor that rarely metastasizes and is readily accessible for local delivery during standard procedures such as biopsy. In vitro assays and preclinical murine studies, including a humanized model with epigenetically silenced STING, demonstrated the antitumor efficacy, specificity, and mechanism of action of IMGS-203. These studies also provided pharmacokinetic data and supported its translational potential for local delivery.
Title:
IND-enabling development of a novel STING agonist, IMGS-203, for the treatment of glioblastoma
Abstract Number:
4300
Date and Time:
Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PT
Session:
Immunomodulatory Agents
Location:
Poster Section 8, Poster Board Number 4
For more information and to view the Company’s abstract, visit the AACR (Free AACR Whitepaper) Annual Meeting website.
(Press release, ImmunoGenesis, APR 15, 2026, View Source [SID1234664409])